Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:04 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Pilot Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
NCT01163799 · Northwestern University · PHASE1 · terminated · last registry update 2013-05-03 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Noted increased risks, greater than expected for standard of care therapy.” | – | Registry record, Northwestern University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2013-08-13Results posted on the registry: Dana-Farber Cancer Institute, Alefacept (NCT01226420)
- 2013-08-13Also stopped (terminated): Dana-Farber Cancer Institute, Alefacept (NCT01226420)
- 2013-04-09Results posted on the registry: University of Minnesota, Alefacept (NCT00167102)
- 2013-02-22Also stopped (terminated): John Murray, alefacept (NCT00953329)
- 2013-02-15Results posted on the registry: University of California, San Francisco, Intralesional Alefacept (NCT00678470)
- 2013-02-15Results posted on the registry: John Murray, alefacept (NCT00953329)
- 2012-08-03Results posted on the registry: Wake Forest University, Alefacept (NCT00655564)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision